Daily Stock List
Seair, Inc. (SDS.V)
Today we are highlighting Seair, Inc. (SDS.V), here at the QualityStocks Daily Newsletter.
Seair, Inc. is a leading developer of proprietary Diffusion technologies in North America and worldwide. The Company's technology allows for the extremely efficient diffusion of gases into liquids. Seair develops proprietary equipment that diffuses gases, such as oxygen, ozone and carbon dioxide, into liquids. Currently, the Company can employ their systems in a broad array of applications in many industries. Seair lists on the TSX Venture Exchange. The Company has their headquarters in Edmonton, Alberta.
The Company's patented technologies can create micron size bubbles that are more efficient than other diffusion technologies. The result is a stable condition, where gases remain in a solution for extended periods, leading to increased productivity and lower operating costs. Subsequently, this facilitates gas-based treatment of complex and challenging wastewater, and allows Seair to provide full water reuse and closed loop systems.
Seair applications include frac and produced water treatment, efficient treatment of industrial ponds, mine dewatering, end-to-end sewage treatment for permanent residential communities and remote work camps, golf course irrigation and pond treatment, and oil sands/SAGD water solutions. The Company's primary focus is developing and selling equipment that diffuses gases such as Oxygen, Ozone and/or CO2 into a liquid, resulting in a supersaturate solution.
The Seair Diffusion Technology process begins with a liquid passing through the Seair system. Gas then undergoes diffusion into the liquid inside the patented Seair Diffusion Chamber. In there, a 5 micron sized bubble is created allowing for the mass transfer of gas to fluid to create a supersaturated fluid. The super saturated fluid is subsequently reintroduced back towards its destination retaining 85 percent of the gas in a stable condition. It is then available for immediate use in a variety of water enhancement applications.
Benefits of the Seair Diffusion System include the optimum use of expensive gases. It diffuses more gas than conventional methods and systems can be designed with the versatility to deliver multiple treatments from one System. The Seair Diffusion System has a low operating cost, is available in an assortment of sizes, is easy to use and maintain, and is environmentally friendly.
Seair, Inc. (SDS.V), closed Monday's trading session at $0.40, up 8.11%, on 85,106 volume. The stock's 52-week low/high is $0.30/$1.39.
Sugarmade, Inc. (SGMD)
We are highlighting Sugarmade, Inc. (SGMD), here at the QualityStocks Daily Newsletter.
Headquartered in San Jose, California, Sugarmade, Inc. engages in marketing and distributing non-tree-based paper products, made from sugarcane bagasse, which is the residual of the sugar manufacturing process, and bamboo. The Company's products include printing, writing and copy paper, among other items. Sugarmade has started marketing these products in the U.S and their intention is to market them worldwide. Founded in 2009, Sugarmade's shares trade on the OTCQB.
The Company is a Benefit Corporation (B Corp). This is a new class of corporation chartered by law to create a material, positive impact on society and the environment. As a B Corp, Sugarmade performs to a higher standard, agrees to transparency and submits to rigorous audits.
Sugarmade™ is 100 percent reclaimed sugarcane fiber, enhanced with bamboo. Sugarcane fiber, bagasse, is a discarded by-product of sugar production. Bagasse is ideal for papermaking. It is denser in cellulose fiber than wood pulp; it produces the same amount of paper with fewer raw materials, less water, less energy and less waste. The finished product is a strong, ultra-white office paper. It is 100 percent biodegradable, compostable and recyclable. Sugarmade's bleaching process is elementally chlorine free (ECF).
Sugarmade multipurpose paper meets or exceeds industry standards. The paper performs on office and home equipment with no issues related to jamming, misfeeding, and paper curl, paper dust, or image performance.
At the beginning of October, Sugarmade announced that they secured a new $3 million production line of credit. The credit line is available to Sugarmade for use beginning with the Company's current production run. The funds will allow them to build inventory for future sales to customers by the Company's regional distributors. Sugarmade anticipates production of 12 containers in October and more than 30 by year-end.
Mr. Scott Lantz, CEO and Chairman of Sugarmade, stated, "We are very pleased with this new financing which we believe will allow us to build inventory in the United States and China to meet the needs of our distribution partners. Additionally, the ability to increase our production volumes will permit us to take advantage of cost efficiencies and the capacity demands of our customers."
Sugarmade, Inc. (SGMD), closed Monday's session at $0.6465, up 26.76, on 500 volume with 1 trade. The average volume for the last 60 days is 5,468 and the stock's 52-week low/high is $0.30/$3.50.
U-Swirl, Inc. (SWRL)
Today we are highlighting U-Swirl, Inc.(SWRL), here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, U-Swirl, Inc. offers an alternative for meals and snacks in the U.S. In October of 2008, they acquired the global rights to U-SWIRL Frozen Yogurt®. The Company has started executing an aggressive strategy to build the brand into a worldwide-recognized chain of highly experiential frozen yogurt stores. The Company formerly went by the name Healthy Fast Food, Inc. They changed their name to U-Swirl, Inc. on May 16, 2011. U-Swirl has their corporate headquarters in Henderson, Nevada.
The original U-Swirl franchise opened in April 2008 in Las Vegas, Nevada. In March 2009, Healthy Fast Food, by way of their wholly owned subsidiary U-Swirl International, Inc., premiered their first Company-owned U-Swirl Frozen Yogurt store in Las Vegas. In less than eight months, there were six U-Swirl stores in operation in the Vegas valley.
U-Swirl guests serve themselves and pay per ounce instead of by the cup size. U-Swirl provides up to 20 non-fat flavors, including tart, traditional and no-sugar options. They provide more than 60 toppings, including seasonal fresh fruit, sauces, candy and granola. Under the U-Swirl system, each store must conform to a standard of interior design, featuring distinctive and comfortable decor.
All goods sold by franchisees must be bought through U-Swirl or U-Swirl-approved suppliers that have met with the Company's strict, high quality specifications and standards. In addition, the yogurt sold in U-Swirl stores must meet the criteria established by the National Yogurt Association for live and active culture yogurt.
In September, U-Swirl, Inc., parent to U-Swirl International, Inc., the owner and franchisor of U-Swirl Frozen Yogurt® cafés, announced that the 31st U-Swirl Café in the chain opened for business in Katy, Texas. This is the first of ten planned locations in the Houston, Texas area. U-Swirl offers an assortment of Fat Free, Low Calorie, as well as Gluten Free frozen yogurts.
U-Swirl, Inc.(SWRL), closed Monday's trading session at $0.28, up 27.27%, on 1,500 volume with 1 trade. The average volume for the last 60 days is 6,329 and the stock's 52-week low/high is $0.10/$0.37.
Capstone Therapeutics Corp. (CAPS)
Wall Street Resources, BestOtc, and SmallCapVoice reported previously on Capstone Therapeutics Corp. (CAPS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Capstone Therapeutics Corp. is a biotechnology company whose shares trade on the OTCQB. The Company's commitment is to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served conditions. On August 3, 2012, Capstone Therapeutics entered into a Joint Venture (the JV) to develop Apo E mimetic peptide molecule AEM-28 and its analogs. Capstone Therapeutics is headquartered in Tempe, Arizona.
Capstone Therapeutics and LipimetiX, LLC, a privately held biopharmaceutical company, announced on August 3, 2012, that they entered into the JV to develop a class of drugs targeted for indications related to lowering blood cholesterol levels. The joint venture, LipimetiX Development LLC (JV), will develop a family of Apo E mimetic peptides licensed from The UAB Research Foundation (UABRF). The University of Alabama at Birmingham (UAB) is a leading research institution in this field.
The intention of the JV is to implement an initial development plan to file an IND and pursue Food and Drug Administration (FDA) approval of AEM-28 as treatment for Severe Refractory Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (as an Orphan Drug). The initial funded development plan will extend through Phase 1a and 1b/2a clinical trials over an expected 27-month period with a biomarker endpoint test targeting reduction of LDL. In addition, the JV may fund research or studies to investigate Apo E mimetic molecules, including AEM-28 and analogs, for the treatment of acute coronary syndrome.
Under the terms of the JV agreement, Capstone Therapeutics will contribute $6 million: $1 million for voting common ownership units representing 60 percent ownership in JV; and $5 million for non-voting preferred ownership units, which have preferential distribution rights. LipimetiX will contribute to the JV their existing license agreement with UABRF related to Apo E mimetic peptides AEM-28 and analogs, in return for voting common ownership units representing 40 percent ownership in the JV.
Concerning Apo E Mimetic Molecule- AEM-28, Apolipoprotein E is a 299 amino acid protein that plays a vital role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E that contains a domain that anchors into a lipoprotein surface while also providing the Apo E binding domain that is avidly removed by heparin sulfate receptors in the liver. AEM-28 replicates the function of Apo E, and because of its small size, extends that function to LDL, which does not usually bind to the Apo E receptors on the liver. Therefore, when AEM-28 undergoes injection into the plasma, it associates with Apo B containing lipoproteins to facilitate their clearance into the liver by receptors specific for Apo E.
Capstone Therapeutics Corp. (CAPS), closed Monday's trading session at $0.17, up 30.77%, on 114,139 volume with 23 trades. The average volume for the last 60 days is 52,872 and the stock's 52-week low/high is $0.122/$0.29.
Rarus Technologies, Inc. (RARS)
Penny Stock Circle, The Stock Scout, Penny Stock Pros, PennyStockClub, StockMarketQuote.us, Greenbackers, and 1-2-3 Stock Alerts reported earlier on Rarus Technologies, Inc.(RARS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Incorporated in 2010, Rarus Technologies, Inc. is an emerging technology company that lists on the OTCQB. The Company is focusing on establishing an innovative business model intended to bridge cutting-edge social media and e-commerce into a marketplace that connects friends, family, consumers, and vendors in new ways. In May 2012, Rarus Technologies incorporated Zngle, Inc. as the primary subsidiary and operations base for the Zngle.com licensed internet platform.
Rarus Technologies is headquartered in Henderson, Nevada. The Company was formerly known as Rarus Minerals, Inc. They changed their name to Rarus Technologies, Inc. in February of 2012.
The design of the Company's Zngle.com is to be a centralized Internet site and next-generation social media website, which incorporates voice/text messaging, video email, and mobile technologies to allow consumers to access real-time information about different products and services via augmented proximity reality search features.
Znlge's objective is to bridge the gap between social media and local commerce. They work with merchants to understand their core business objectives. Znlge's commitment is to creating action plans for full online, social media, and mobile integration. Their proprietary research and trade data helps merchants define their target markets and understand important consumer buying trends.
Zngle will garner revenue through selling banner space. This will be viewable by people who are within the advertiser's relevant geographic location and who display the appropriate interest criteria. Zngle will gather this specific user information by tracking accessed content, 'liked' items, as well as profile information. Additionally, Zngle will incorporate a bidding strategy on all banner inventories to ensure maximum revenues.
Zngle.com will offer augmented reality coupons that feature proximity alerts for specific merchants. Zngle members will receive alerts by way of push notification on their smartphones when they are close to a business offering a coupon. Members can redeem an offer through displaying the mobile coupon at the point of purchase.
This month, Rarus Technologies announced that their version 1.3 of the Zngle iPhone App is now available at the Apple iTunes Store. The Company's Zngle social media network released their version 1.3 with VoIP calling. It has features such as Video email, chat, group chat, augmented reality, friend and family locator, private messaging, video calling as well as VoIP calling.
Rarus Technologies, Inc. (RARS), closed Monday at $0.0125, up 38.89%, on 346,690 volume with 18 trades. The average volume for the last 60 days is 400,172 and the stock's 52-week low/high is $0.0051/$0.59.
Nyxio Technologies Corp. (NYXO)
Wallstreetbuzz, Club Penny Stocks Network, 1-2-3 Stock Alerts, The Stock Scout, Penny Stock Pros, Penny Stock Circle, StockMarketQuote.us, PennyStockClub, KO PENNY STOCKS, and Momentum Hunter reported earlier on Nyxio Technologies Corp. (NYXO), we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Nyxio Technologies Corp. designs and markets a line of innovative consumer electronic devices. The Company's products offer distinctive features such as touch screen controls, built-in Bluetooth capabilities, and wireless video features, which are all bundled into practical and creative packages. Their flagship product is the VioSphere TruSmart TV. Founded in 2007, Nyxio Technologies has their headquarters in Portland, Oregon.
The VioSphere TruSmart TV is the first fully integrated flat screen TV and full Personal Computer (PC) available on the market. VioSphere is a full-spectrum entertainment system. It combines HDTV technology with a personal computer and media center. Its touch-screen feature enables easy navigation via several applications. Additionally, the split-screen design accommodates viewing television, films, videos, games or Web conferences while at the same time viewing content by way of television or PC.
Nyxio also offers their Nyxio Venture MMV (Mobile Media Viewer). This is a new class of personal, portable video eyewear. The Venture MMV is compatible with most video and audio formats. It delivers very clear high-resolution, and the built-in comfort ear buds provide premier sound quality to an individual's personal cinema. The USB and micro SD interface allows easy and high-speed file uploading of all of one's favorite media to a wide screen virtual display in a non-traditional LCD panel.
In addition, the Company offers their Vuzion Smart TV with Android OS. The Nyxio Vuzion combines a high definition LED TV, Internet, and Android OS. It has a webcam, wireless remote, built-in microphone, and speakers. This HD television offers HDMI, VGA, USB, web browsing, stored personal content, and gaming.
Furthermore, Nyxio offers their Nyxio Ascend Smart Keyboard. Ascend is a keyboard and personal computer in one design. With the Ascend, a user gets the versatility and portability of a laptop with the benefit of transforming any TV or monitor into a fully functioning computer. It houses the PC within the keyboard. In addition, Nyxio offers the Nyxio Realm All-In-One PC/TV. It combines the latest in PC technology with HDTV. The full HD 22" touch screen allows unlimited simple access to the Internet, digital TV, social networks, movies, music and more, and it is integrated with the Windows 7 Operating System. The Realm comes complete with built-in WiFi, Camera, Microphone, DVD player and Bluetooth.
Nyxio Technologies Corp. (NYXO), closed today at $0.0156, up 4.00%, on 211,495 volume with 10 trades. The average volume for the last 60 days is 230,569 and the stock's 52-week low/high is $0.012/$0.47.
Ossen Innovation Co., Ltd. (OSN)
PennyOmega, DrStockPick, CRWEWallStreet, CRWEFinance, StockHotTips, BestOtc, PennyToBuck and CRWEPicks reported earlier on Ossen Innovation Co., Ltd. (OSN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Ossen Innovation Co., Ltd. manufactures and sells a broad spectrum of plain surface pre-stressed steel materials and rare earth coated and zinc coated pre-stressed steel materials. The primary use of their products is for the construction of bridges, as well as in highways and other infrastructure projects. The Company has two manufacturing facilities located in Maanshan, Anhui Province, and Jiujiang, Jiangxi Province. Founded in 2004, Ossen Innovation's shares trade on the NASDAQ Global Market.
In addition to regular zinc coating, the Company also uses rare earth in the coating. Rare earth coated products are materials that are zinc coated with a rare earth zinc-plating protective layer to produce materials that are more corrosion-resistant and long lasting. Rare earth coated materials primarily use cerium, lanthanum and other rare earth elements. For uncoated products, their plain surface products include plain surface steel wires and strands that are often used in precast concrete plates.
The Company is one of four manufacturers of coated steel materials in China, equipped with proprietary processing processes. The Jiujiang facility has 50,000 tons of annual capacity for coated products and the Maanshan facility has 90,000 tons of annual capacity for uncoated products. Ossen has now added an additional 30,000 tons of coated products capacity at their existing facility in Maanshan, which brings their total capacity to 170,000 tons a year.
Through the Maanshan facility, Ossen has been manufacturing plain surface PC strands and PC wires since 2004. These products sell primarily in Anhui Province, Jiangsu Province, Zhejiang Province and Shanghai City.
Through the Jiujiang facility, they manufacture coated PC wires and strands, plain surface PC strands, unbonded PC strands, spiral ribbed PC wires, sleeper PC wires and indented PC wires. These products mainly sell in Jiangxi Province, Wuhan City, Hunan Province, Fujian Province and Sichuan Province.
The Company's fastest growing product segment is the galvanized pre-stressed steel wires used by bridge cables. Ossen applies their unique rare earth coating technology in the production of most of their galvanized products.
Recently, Ossen Innovation announced that they would hold their 2012 Annual General Meeting of Shareholders at 10:00 a.m. local time on December 3, 2012 at the Company's headquarters located at 518 Shangcheng Road, Floor 17, Shanghai, China.
Ossen Innovation Co., Ltd. (OSN), closed Monday's trading session at $0.94, even for the day. The average volume for the last 60 days is 5,913 and the stock's 52-week low/high is $0.72/$1.66.
VelaTel Global Communications, Inc. (VELA)
Greenbackers and Wallstreetlivechat reported recently on VelaTel Global Communications, Inc. (VELA), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Founded in May 2008, VelaTel Global Communications, Inc. is a holding company of telecommunications carriers globally. They provide capital and technical expertise to deploy wireless broadband telecommunications networks. The Company subsequently operates those networks through offering services attractive to residential, enterprise and government subscribers and to other network operators. VelaTel Global Communications lists on the OTCQB; the Company is based in Carlsbad, California. Additional offices are in San Isidro, Lima-Perú, and Beijing, China.
Currently, VelaTel holds investments in nine projects. These are GO MOVIL, Novi-Net, Montenegro Connect, Zapna, Sino Crossings, New Generation Special Network (NGSN), Aerostrong Company Ltd., Golden Bridge Network Communications, (GBNC), and VN technologies Co., Ltd.
VelaTel's current operational focus is on the deployment of telecommunications networks that employ Wireless Broadband Access (WBA) in emerging global markets using either the 2.5 GHz or 3.5 GHz radio frequency spectrum. The Company's current markets are in Peru, Eastern Europe and The People's Republic of China (PRC). VelaTel is investigating opportunities to enter other markets. These include Russia, India, Singapore, the Philippines, Albania, countries in the Caribbean Islands and Southern Pacific Islands, and countries in the Middle East and North Africa.
Concerning recent developments for the Company, in June 2012, the VelaTel subsidiary Zapna signed a new distribution agreement in Norway to extend further the Zapna brand outside Denmark. In July 2012, the Zapna subsidiary signed a new Distribution Agreement in Spain to continue their international expansion; VelaTel's subsidiary VN Tech advanced their plans for green energy technology in China; Zapna signed a new Strategic Partnership Agreement with Interfone International, and wireless broadband equipment for VelaTel's Balkans projects arrived on schedule.
VelaTel Global Communications has been accepted to membership in Global TD-LTE Initiative (GTI), a prestigious industry trade group. Global TD-LTE Initiative (GTI) is a virtual open platform to advocate cooperation among global operators to promote TD-LTE. GTI's objective is to bring together the leading operators to steer the TD-LTE ecosystem as a major standard in mobile broadband technology and drive early development of next generation mobile broadband networks.
Last week, VelaTel Global Communications announced that their Zapna subsidiary launched their Zero Call Free™ service in Germany. Zero Call Free™ enables customers to make free calls from their mobile phones. They can call to the U.S. and to over 60 listed countries inside and outside Europe, including China and Canada. If a customer desires to call countries not listed, they utilize Zero Call Out™ through installing Zapna's paper-thin SIM card directly on top of the customer's existing SIM card. This patented device and service allows customers throughout Germany to lower their cost for international calls significantly - up to 90 percent - without changing their current carrier or mobile phone plan.
VelaTel Global Communications, Inc. (VELA), closed Monday's trading session at $0.043, up 53.57%, on 978,723 volume with 88 trades. The average volume for the last 60 days is 442,086 and the stock's 52-week low/high is $0.013/$18.90.
Skinny Nutritional Corp. (SKNY)
The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.002, off by 4.76%, on 1,694,718 volume with 18 trades. The stock’s average daily volume over the past 60 days is 1,348,158, and its 52-week low/high is $0.002/$0.038.
Skinny Nutritional Corp. reported entry into a Standstill Agreement today with Trim Capital LLC, which will act as a framework for continued discussion about the status and obligations associated with the June 28, Securities Purchase Agreement whereby Trim Capital agreed to purchase some $9M in total equity securities via private placement. After clearing the $1M senior secured Initial Note on June 28 and a subsequent senior secured note for $270k on Aug 14, the Aug 28-slated second closing did not occur, and thus we have a Standstill Agreement and 60-day cooling off period.
Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.
The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.
The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.
Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer
Skinny Nutritional Corp. Blog
Skinny Nutritional Corp. News:
Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital
Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $4.06, up 7.41%, on 37,420 volume with 39 trades. The stock’s average daily volume over the past 60 days is 40,297, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.203, off by 1.46%, on 333,740 volume with 104 trades. The stock’s average daily volume over the past 60 days is 259,074, and its 52-week low/high is $0.1771/$0.49.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
DUMA - Duma Energy Corp, Zacks Initiating Coverage
Duma Energy Corp. Partners with Hydrocarb to Explore for World Class Reserves in Africa Oil Concession
Duma Energy Receives Approval From Government of Namibia for Exploration License Issued for 5.3 Million-Acre Concession
GreeneStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreeneStone Healthcare Corp. (GRST). Today, GreeneStone Healthcare Corp. closed trading at $1.75, even with yesterday's close, on 5,129 volume with 16 trades. The stock’s average daily volume over the past 60 days is 16,563, and its 52-week low/high is $0.70/$1.83.
GreeneStone Healthcare Corp. (GRST) is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.
Ontario's public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.
Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.
The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry. Disclaimer
GreeneStone Healthcare Corp. Company Blog
GreeneStone Healthcare Corp. News:
GreeneStone Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
GreeneStone Supports the Cause of Mental Health with Charitable Foundation
GreeneStone Muskoka Once Again Featured on Intervention Canada
Skinny Nutritional, the maker of Skinny Water® and a leader in the zero-calorie enhanced water category, has entered into a Standstill Agreement with Trim Capital LLC. The two companies will continue discussions regarding the status of, and obligations under, the Securities Purchase Agreement dated June 28, 2012 (the “Purchase Agreement”).
Under this agreement, Trim Capital agreed to purchase an aggregate of $9.0 million of equity securities in a private placement transaction, subject to certain conditions. At the first closing, which was completed on June 28, 2012, Skinny Nutritional sold a $1,000,000 senior secured note (the “Initial Note”) to Trim Capital. Later, on August 14, 2012, the company sold an additional initial senior secured note in the aggregate principal amount of $270,000 which was deemed part of the “Initial Note.” The Purchase Agreement provided for a second closing, subject to certain conditions, to be held on or prior to August 28, 2012, which has not occurred.
Following a period of discussion, Skinny Nutritional and Trim Capital have agreed to enter into the Standstill Agreement under which they will have a 60-day period to discuss a plan with respect to the obligations under the Purchase Agreement and the Initial Note. The agreement terminates the prohibition against Skinny Nutritional soliciting alternative transactions and enables the company to pursue various strategic and/or financing alternatives in order to address its obligations and to provide for additional working capital. In addition, the Standstill Agreement provides that the parties will refrain from commencing or prosecuting any claims against the other or their respective affiliates during the standstill period.
For additional information, visit the company’s websites at www.SkinnyWater.com
VistaGen Therapeutics, the rapidly evolving biotech firm that is advancing a stem cell-based technology platform focused on controlling pluripotent stem cell differentiation for application in drug rescue initiatives and next generation pharmaceutical assays for testing potential heart and liver toxicity of new drugs, possesses a game-changing bioassay system with CardioSafe 3D™.
Here we have a stable test bed derived from stem cells differentiated into mature human heart cells that can be used to screen drug candidates for in vivo cardiac results (toxic or nontoxic) with an incredible degree of accuracy due to how closely the bioassay system approximates human cardiac biology. This bioassay technology is far superior to animal testing and provides an alternative to human testing which normally takes many years and millions of dollars to advance through all of the necessary procedures required to get meaningful data, at which point toxic effects could render much of the expended effort wasted.
With a proprietary and licensed method for constructing 3D micro-heart cultures that mature into complete tissue structures, VSTA has their hands on the brass ring of predictive toxicology in a format that overcomes the competition due to mirroring what an actual human trial would potentially look like. Moreover, these 3D tissue structures produce a much higher fidelity data feed than traditional flat 2D assays, which don’t really function properly for a whole range of reasons that basically come down to actual tissues not existing in the body as a thin, isolated 2D slice, but rather as 3D cell networks.
CardioSafe 3D gives drug development efforts a clinically relevant framework in which to gauge the effects of a drug candidate on the heart long before human testing would ever be possible, potentially saving millions and also offering a massive pipeline for drug rescue in the event that a drug is found unsafe and subsequently discontinued. In fact, this is where VSTA has stepped in strategically to capture otherwise promising drug candidates that have been shelved due to heart (and eventually liver) toxicity, leveraging the power of their Human Clinical Trials in a Test Tube™ technology platform to identify and pursue safer drug rescue variants with all the efficacy of the original, but without the toxic effects. CardioSafe 3D mature heart cells even represent a superior, more expedient methodology than nonclinical in vitro techniques currently employed in drug development by most of the pharmaceutical companies in the field today.
Drug development these days can cost Big Pharma in the neighborhood of around $800M to $1.7B, possibly billions more, while taking ten to fifteen years to commercialize just one candidate. Having to mothball a candidate after that kind of capital outlay is a huge set back. In fact, one in three potential new drugs ends up this way and that is why the company has been gearing up to unearth the buried investments. New technology like the company’s LiverSafe 3D™, a cell-based bioassay system in development utilizing human liver cells derived from stem cells, shows the extensibility of VSTA’s drug rescue capabilities and this sort of bioassay/drug rescue variant synergy should tell investors a great deal about the future of such packaged culture analysis using stem cell derived tissue.
It is the clear technological might of this stem cell based platform that spells abundant licensing potential for the bioassay applications in drug development, and one must marvel at the true, long-term possibilities with controlled differentiation of human pluripotent stem cells into mature, fully functional cell types for vetting a whole range of chemical interactions and drug rescue opportunities. It is as close to a human on a chip as anyone is getting today, and with a slew of companies jumping into the thriving research model business, VSTA represents a compelling alternative with a boldly unique IP portfolio.
Harvesting the vast profitability from a diverse, proprietary array of small molecule drug rescue candidates, redeemed from discontinuation after large investments by pharmaceutical giants and chosen for positive preclinical vectors, is a really good strategy for VSTA and its extensive ecosystem of drug rescue collaborators. In today’s pharmaceutical marketplace, with the skyrocketing costs of drug development and threats from generic competition, the strength and necessity of the human clinical trials in a test tube cannot be denied. The ability of in vitro bioassay technologies like CardioSafe 3D andLiverSafe 3D™ to address the FDA’s modest annual approval rate of new drugs over the last ten years (only about 25 per year) is obvious.
For more information, visit the company’s website www.VistaGen.com
Texas-based Teletouch Communications, a long-standing communications and consumer electronics company, has been going through a significant transition, restructuring itself into becoming a nationwide communications/consumer electronics distribution leader. It’s a change made possible by the fact that the company’s management team has been with Teletouch for many years. Members of the team have an intimate knowledge of the company and the communications/electronics industry.
Refocusing a corporation can affect every operational aspect, from management and marketing, to distribution and finance. An executive team that is 100% behind the move, in addition to being able to draw on a combined familiarity with every aspect of the company’s operations, together with a long history in the industry, gives a directional change every chance of success.
The Teletouch team has enough experience working together and guiding the company through various successful acquisitions over the past decade that the chance of a misstep is greatly reduced.
• Robert M. McMurrey (Chairman, CEO) has over 25 years with the wireless industry, and has been a controlling shareholder of the predecessor to Teletouch for longer than that. He guided the company’s original expansion with the completion of 16 acquisitions, including the acquisition of PCI, the company’s major distribution arm, in 2001. He has extensive experience in acquiring, financing, and operating wireless and other companies.
• Thomas ‘Kip’ A. Hyde, Jr. (President, COO) has been with Teletouch since 2002, and was key to the restructuring, operation, and later divestiture of the Hawk Security Home & Commercial Services unit of PCI for a substantial ROI. He has far-reaching experience in corporate mergers and acquisitions, in addition to Fortune 500 senior management experience.
• Douglas E. Sloan (CFO) has been with Teletouch since 1998, and has comprehensive experience in the financial aspects of mergers and acquisitions. He also carries a CPA, and was a Sr. Auditor with Ernst & Young.
• Michael A. Dickens (SVP Operations) joined PCI, now part of Teletouch, in 1995, and has many years of experience in retail operations, marketing, and merchandising.
• Steven S. Carpenter (SVP Information Technology), one of PCI’s original employees, developed the company’s CRM, Billing, and Customer Service IT systems.
• Debbie J. Schreier (VP Human Resources), CPA, MBA, and one of the company’s longest employees, is now responsible for all company HR operations.
• Timmy Monico (Wholesale Distribution Division Head) is a 30-year veteran of the wireless and distribution industries, and is the newest addition to the team.
To learn more about Teletouch, visit www.TeleTouch.com
Silver Falcon Mining, a junior gold and silver developer with mineral rights to a substantial 1,200 acres (War Eagle Mountain) within southern Idaho’s prolific Owyhee Gold Trend, announced today that Mr. Paul Parliament, a shareholder since the company’s inception back in late 2007, will bring his vast experience and keen eye for business strategy to the company’s Board of Directors.
Today’s announcement follows fast on the heels of the Oct 18 operational update regarding a bevy of updates at the company’s Sinker Tunnel Complex (provides sub $200/oz, low cost access to a broad array of mineralized veins throughout the mountain above, like the 10k-foot long Oro Fino Vein System originally tapped back in the 1800s), Diamond Creek Mill, and Metallurgical Facilities at the foot of War Eagle Mountain. With the BLM approving the company’s site plan for securing Sinker tunnel area logistics needed to facilitate underground work, the appointment of a corporate finance, management, permitting, planning, property acquisition, and staffing veteran like Parliament is just the ticket SFMI needs to punch through to the next level with their War Eagle Mountain operation.
Formerly, Mr. Parliament was President of several notable, prominent real estate firms (Marsadi Layne Properties, Inc.; P.D.P Developments, Inc.; The Parliament Corp.; The Parliament Apartment Corp.) and now possesses a kind of organically developed instinct for all matters pertaining to financial structuring. It is this finance and structural know-how muscle he will flex as a Director of SFMI, helping Silver Falcon realize the boundless potential inherent in the War Eagle operation. With a track record that includes several direct investments into the company that have aided management in securing key functional milestones, Parliament is clearly a diehard player who will bring considerable push to the team.
Parliament himself noted his emergence from being a big shareholder to becoming a more “integral part” of the company’s story, driven in large part by the bounty of the War Eagle mineralization and the extent of the project’s total development. The work done at War Eagle from back in the late 1800s shows clear indications that there was a potentially large amount of ore above the two ounce cut-off (economic grade back then) in the underground drifts and stopes being actively sought after. With a solid 0.375 opt ore that can be readily mined today at a handsome profit, the upside for investors is tantalizing indeed. Management’s analysis is pretty straight forward here and the argument that the historic Golden Chariot developments wouldn’t have been done, unless the 2.0 opt deeper resource was present, is sound.
Board members Christian Quilliam, Denise Quilliam, Lewis Georges Allan Breitkreuz, Pierre Quilliam, and Tom Ridenour heartily approved the appointment.
The recent Diamond Creek Mill expansion was shown off to shareholders at the Sept 21 annual meeting, as well as impressive progress at the facility’s new Metallurgical Lab, with the meeting giving participants an opportunity to witness the biggest precious metal dore pour to date, at roughly 240 ounces. Today’s appointment is just another piece in the puzzle and it all comes just the week after securing necessary equipment and personnel for ramping up via the Sinker Tunnel Complex (including excavation, loader, mine personnel carrier, secure fencing, and a snow plow, as well as a lead hand for the tunnel work and 15 MSHA-certified underground workers).
You can visit the Silver Falcon Mining website if you would like more information on this exciting precious metals junior:www.SilverFalconMining.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund